Unknown NA INTERVENTIONAL 2-arm NCT01406600

Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles

Optimal rhCG(Ovidrel®) Dose for Final Oocyte Maturation Triggering in Poor Responder During IVF and ICSI Cycles

Sponsor: Seoul National University Hospital

Conditions Poor Responder in Vitro Fertilization

Interventions recombinant hCG (Ovidrel®)

Updated 6 times since 2017 Last updated: Apr 11, 2013 Started: Sep 30, 2011 Primary completion: Nov 30, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01406600, this NA trial focuses on Poor Responder and in Vitro Fertilization and remains ongoing. Sponsored by Seoul National University Hospital, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown NA
Sep 2024 — Sep 2025 [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status NA

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Seoul National University Hospital

Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea